The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease

Expert Review of Hematology

Volumn 4, Issue 6, 2011, Pages 597-606

  Strouse, John J ^a   Lanzkron, Sophie ^a   Urrutia, Victor ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

epidemiology; hydroxyurea; intracranial hemorrhage; ischemic stroke; sickle cell disease; subarachnoid hemorrhage; transfusion

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

AGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DIABETES MELLITUS; EXCHANGE BLOOD TRANSFUSION; GENETIC RISK; GENOTYPE; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SICKLE CELL ANEMIA; STROKE; SYSTOLIC BLOOD PRESSURE;

ANEMIA, SICKLE CELL; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; HUMANS; RISK FACTORS; STROKE;

EID: 81255210779     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.61     Document Type: Review

References (76)

1. Sydentricker V, Mulherin W, Houseal R. Sickle cell anemia: Report of two cases in children with necropsy in one case. Am. J. Dis. Child. 26, 132-154 (1923).
2. Obama MT, Dongmo L, Nkemayim C, Mbede J, Hagbe P. Stroke in children in Yaounde, Cameroon. Indian Pediatr. 31(7), 791-795 (1994).
3. Ohene-Frempong K, Weiner SJ, Sleeper LA et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 91(1), 288-294 (1998). (Pubitemid 28018756)
4. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am. J. Med. 65(3), 461-471 (1978). (Pubitemid 8397664)
5. Kissela B, Schneider A, Kleindorfer D et al. Stroke in a biracial population: The excess burden of stroke among blacks. Stroke 35(2), 426-431 (2004). (Pubitemid 38174424)
6. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine (Baltimore) 84(6), 363-376 (2005). (Pubitemid 41668935)
7. Strouse JJ, Jordan LC, Lanzkron S, Casella JF. The excess burden of stroke in hospitalized adults with sickle cell disease. Am. J. Hematol. 84(9), 548-552 (2009).
8. Njamnshi AK, Mbong EN, Wonkam A et al. The epidemiology of stroke in sickle cell patients in Yaounde, Cameroon. J. Neurol. Sci. 250(1-2), 79-84 (2006). (Pubitemid 44665933)
9. Kehinde MO, Temiye EO, Danesi MA. Neurological complications of sickle cell anemia in Nigerian Africans - a case- control study. J. Natl Med. Assoc. 100(4), 394-399 (2008). (Pubitemid 351556498)
10. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J. Pediatr. 120(3), 360-366 (1992).
11. Jacobs BS, Boden-Albala B, Lin I-F, Sacco RL. Stroke in the young in the Northern Manhattan Stroke Study. Stroke 33(12), 2789-2793 (2002). (Pubitemid 35462845)
12. Strouse JJ, Hulbert ML, Debaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 118(5), 1916-1924 (2006). (Pubitemid 46393673)
13. Pegelow CH, Colangelo L, Steinberg M et al. Natural history of blood pressure in sickle cell disease: Risks for stroke and death associated with relative hypertension in sickle cell anemia. Am. J. Med. 102(2), 171-177 (1997). (Pubitemid 27122999)
14. Wierenga KJ, Serjeant BE, Serjeant GR. Cerebrovascular complications and parvovirus infection in homozygous sickle cell disease. J. Pediatr. 139(3), 438-442 (2001). (Pubitemid 32889523)
15. Scothorn DJ, Price C, Schwartz D et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J. Pediatr. 140(3), 348-354 (2002). (Pubitemid 34289713)
16. Dobson SR, Holden KR, Nietert PJ et al. Moyamoya syndrome in childhood sickle cell disease: A predictive factor for recurrent cerebrovascular events. Blood 99(9), 3144-3150 (2002). (Pubitemid 34525291)
17. Strouse JJ, Field J, Crawford RD, Lanzkron S. Antecedent transfusion and primary hemorrhagic stroke in adults with sickle cell disease. ASH Annual Meeting Abstracts 112(11), 1437 (2008).
18. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat. Genet. 37(4), 435-440 (2005).
19. Adams R, Mckie V, Nichols F et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N. Engl. J. Med. 326(9), 605-610 (1992).
20. Adams RJ, Mckie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med. 339(1), 5-11 (1998). (Pubitemid 28304491)
21. Silva G, Vicari P, Figueiredo M, Junior H, Idagawa M, Massaro A. Migraine-mimicking headache and sickle cell disease: A transcranial Doppler study. Cephalalgia 26(6), 678-683 (2006).
22. Valadi N, Silva GS, Bowman LS et al. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology 67(4), 572-574 (2006). (Pubitemid 44273600)
23. Silva GS, Vicari P, Figueiredo MS, Junior HC, Idagawa MH, Massaro AR. Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease correlation with transcranial doppler findings. Stroke 40(7), 2408-2412 (2009).
24. Latchaw RE, Alberts MJ, Lev MH et al. Recommendations for imaging of acute ischemic stroke. Stroke 40(11), 3646-3678 (2009).
25. Deane CR, Goss D, Bartram J et al. Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica 95(8), 1287-1292 (2010).
26. Jordan LC, Strouse JJ. Will submandibular TCD prevent stroke in children with sickle cell anemia? Neurology 73(5), 340-341 (2009).
27. Brott TG, Halperin JL, Abbara S et al.; ASA/ACCF/AHA/AANN/AANS/ACR/ ASNR/CNS/SAIP/SCAI/SIR/SNIS/ SVM/SVS. Guideline on the management of patients with extracranial carotid and vertebral artery disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography. J. Am. Coll. Cardiol. 57(8), 1002-1044 (2011).
28. Banna M. Post-angiographic blindness in a patient with sickle cell disease. Invest. Radiol. 27(2), 179-181 (1992).
29. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N. Engl. J. Med. 287(17), 846-849 (1972).
30. Oyesiku NM, Barrow DL, Eckman JR, Tindall SC, Colohan AR. Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis. J. Neurosurg. 75(3), 356-363 (1991).
31. Furie KL, Kasner SE, Adams RJ et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(1), 227-276 (2011).
32. Vicari P, Sampaio Silva G, De Cassia Rosario Cavalheiro R, Massaro AR, Figueiredo MS. Fulminant stroke in an adult patient with sickle cell anemia. Acta Haematol. 116(1), 67-69 (2006). (Pubitemid 43990961)
33. Jayabose S, Sheikh F, Mitra N. Exchange transfusion in the management of CNS crisis in sickle cell disease. Clin. Pediatr (Phila.) 22(11), 776-777 (1983). (Pubitemid 14230449)
34. Huttenlocher PR, Moohr JW, Johns L, Brown FD. Cerebral blood flow in sickle cell cerebrovascular disease. Pediatrics 73(5), 615-621 (1984). (Pubitemid 14143970)
35. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke. Stroke 40(7), 2438-2441 (2009).
36. Adams HP Jr, Del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 115(20), e478-e534 (2007).
37. Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RA, Donnan GA. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc. Dis. 20(4), 239-244 (2005). (Pubitemid 41318201)
38. Stroke Unit Trialists Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst. Rev. 4, CD000197 (2007).
39. Charneski L, Congdon HB. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature. Am. J. Health Syst. Pharm. 67(11), 895-900 (2010).
40. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. Am. Heart J. 162(1), 115-124.e2 (2011).
41. Powars D, Adams RJ, Nichols FT, Milner P, Charache S, Sarnaik S. Delayed intracranial hemorrhage following cerebral infarction in sickle cell anemia. J. Assoc. Acad. Minor Phys. 1(3), 79-82 (1990).
42. Willey JZ, Elkind MSV. Stroke: do statins improve outcomes after acute ischemic stroke? Nat. Rev. Neurol. 7(7), 364-365 (2011).
43. Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: Effects on markers of vascular dysfunction. Br. J. Haematol. 153(5), 655-663 (2011).
44. Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. Am. J. Dis. Child. 133(12), 1254-1257 (1979). (Pubitemid 10205404)
45. Wilimas J, Goff JR, Anderson HR Jr, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J. Pediatr. 96(2), 205-208 (1980). (Pubitemid 10129397)
46. Wang WC, Kovnar EH, Tonkin IL et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J. Pediatr. 118(3), 377-382 (1991).
47. Rana S, Houston PE, Surana N, Shalaby- Rana EI, Castro OL. Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke. J. Pediatr. 131(5), 757-760 (1997). (Pubitemid 27524860)
48. Hulbert ML, Mckinstry RC, Lacey JL et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 117(3), 772-779 (2011).
49. Greenway A, Ware RE, Thornburg CD. Long-term results using hydroxyurea/ phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am. J. Hematol. 86(4), 357-361 (2011).
50. Ware RE, Helms RW. Stroke with transfusions Changing to Hydroxyurea (SWiTCH): A Phase 3 randomized clinical trial for treatment of children with sickle cell anemia, previous stroke, and iron overload. ASH Annual Meeting Abstracts 116(21), 844 (2010).
51. Ali SB, Moosang M, King L, Knight- Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am. J. Hematol. 86(10), 846-850 (2011).
52. Walters MC, Hardy K, Edwards S et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol. Blood Marrow Transplant. 16(2), 263-272 (2010).
53. Woodard P, Helton KJ, Khan RB et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br. J. Haematol. 129(4), 550-552 (2005). (Pubitemid 40769906)
54. Hsieh MM, Kang EM, Fitzhugh CD et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361(24), 2309-2317 (2009).
55. Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant 42(8), 523-527 (2008).
56. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr. Neurol. 29(2), 124-130 (2003). (Pubitemid 37324384)
57. Hankinson TC, Bohman LE, Heyer G et al. Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J. Neurosurg. Pediatr. 1(3), 211-216 (2008). (Pubitemid 351346510)
58. Smith ER, Mcclain CD, Heeney M, Scott RM. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg. Focus 26(4), E10 (2009).
59. Mendelow AD, Gregson BA, Fernandes HM et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): A randomised trial. Lancet 365(9457), 387-397 (2005). (Pubitemid 40179225)
60. Morgenstern LB, Hemphill JC 3rd, Anderson C et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 41(9), 2108-2129 (2010).
61. Bederson JB, Connolly ES, Batjer HH et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke 40(3), 994-1025 (2009).
62. Mcconachie NS, Jaspan T, Hatrick AG et al. Complications of sickle cell disease: Intracranial aneurysms and their treatment. Clin. Radiol. 53(5), 388-389 (1998).
63. King AA, White DA, Mckinstry RC, Noetzel M, Debaun MR. A pilot randomized education rehabilitation trial is feasible in sickle cell and strokes. Neurology 68(23), 2008-2011 (2007). (Pubitemid 46869705)
64. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 377(9778), 1693-1702 (2011).
65. Wang W, Enos L, Gallagher D et al. Neuropsychologic performance in school-aged children with sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. J. Pediatr. 139(3), 391-397 (2001). (Pubitemid 32889516)
66. Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro OL. Homocysteine in sickle cell disease: Relationship to stroke. Am. J. Med. 103(3), 192-196 (1997). (Pubitemid 27413401)
67. Miller ST, Macklin EA, Pegelow CH et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. J. Pediatr. 139(3), 385-390 (2001). (Pubitemid 32889515)
68. Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet 357(9269), 1656-1659 (2001). (Pubitemid 32568239)
69. Adams RJ, Mckie VC, Carl EM et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann. Neurol. 42(5), 699-704 (1997). (Pubitemid 27481541)
70. Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: Extended analysis from the STOP trial. Br. J. Haematol. 134(3), 333-339 (2006). (Pubitemid 43990798)
71. Flanagan JM, Frohlich DM, Howard TA et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 117(24), 6681-6684 (2011).
72. Adams RJ, Kutlar A, Mckie V et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am. J. Hematol. 45(4), 279-282 (1994). (Pubitemid 24109901)
73. Hoppe C, Klitz W, Cheng S et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood 103(6), 2391-2396 (2004). (Pubitemid 38326263)
74. Taylor JGT, Tang DC, Savage SA et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 100(13), 4303-4309 (2002). (Pubitemid 35429667)
75. Tang DC, Prauner R, Liu W et al. Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: A case-control study. Am. J. Hematol. 68(3), 164-169 (2001). (Pubitemid 32983204)
76. Romana M, Diara JP, Doumbo L et al. Angiotensinogen gene associated polymorphisms and risk of stroke in sickle cell anemia: Additional data supporting an association. Am. J. Hematol. 76(3), 310-311 (2004).(Pubitemid 38828861)